Navigation path

NeutNet


HIV/AIDS

Standardisation of HIV Neutralisation Assays to be Used in Vaccine Research and Clinical Trials
Framework programme:
6
Call:
2
Project number:
LSSP-CT-2004-012190
EC contribution:
€ 299,000
Duration:
27 months
Type:
SSA
Starting date:
1 January 2005

Keywords: HIV; neutralising antibody; standardisation

Summary:

The relevance of neutralising antibodies in protection against HIV infection and disease remains to be elucidated. Numerous in vitro neutralisation assays have been developed, each one with different variables and endpoints. NeutNet, a group of 14 participants from all over the world, proposes to coordinate activities aimed at standardising methods for the measurement of neutralising antibodies to HIV-1 for use in human clinical trials of candidate AIDS vaccines. NeutNet will organise an initial study with the most relevant neutralisation methods and a panel of well-characterised and common reagents, to define appropriate reference controls for neutralisation assays. The data from this study will serve as the basis for a subsequent study with polyclonal serologic reagents to gain an understanding of the prerequisites to measure accurately and reproducibly HIV-1 functional antibodies for HIV protection and pathogenesis. A workshop, jointly organised with World Health Organization (WHO)/Joint United Nations Programme on HIV/AIDS (UNAIDS), will provide a venue to discuss the results of the actions of NeutNet with a larger body of researchers in the field and share the information at a global level. The results of NeutNet will benefit HIV vaccine research and clinical trials, making it possible to compare all vaccine efforts throughout Europe and beyond.

[+] Read More